Literature DB >> 17154430

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

Zhengying Pan1, Heleen Scheerens, Shyr-Jiann Li, Brian E Schultz, Paul A Sprengeler, L Chuck Burrill, Rohan V Mendonca, Michael D Sweeney, Keana C K Scott, Paul G Grothaus, Douglas A Jeffery, Jill M Spoerke, Lee A Honigberg, Peter R Young, Stacie A Dalrymple, James T Palmer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17154430     DOI： 10.1002/cmdc.200600221

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  197 in total

1.  A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site Identification.

Authors:  Christopher M Browne; Baishan Jiang; Scott B Ficarro; Zainab M Doctor; Jared L Johnson; Joseph D Card; Sindhu Carmen Sivakumaren; William M Alexander; Tomer M Yaron; Charles J Murphy; Nicholas P Kwiatkowski; Tinghu Zhang; Lewis C Cantley; Nathanael S Gray; Jarrod A Marto
Journal:  J Am Chem Soc       Date:  2018-12-20       Impact factor: 15.419

Review 2.  Targeting protein kinases with selective and semipromiscuous covalent inhibitors.

Authors:  Rand M Miller; Jack Taunton
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

3.  A computational workflow for the design of irreversible inhibitors of protein kinases.

Authors:  Alberto Del Rio; Miriam Sgobba; Marco Daniele Parenti; Gianluca Degliesposti; Rosetta Forestiero; Claudia Percivalle; Pier Franco Conte; Mauro Freccero; Giulio Rastelli
Journal:  J Comput Aided Mol Des       Date:  2010-03-21       Impact factor: 3.686

Review 4.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

5.  Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.

Authors:  Li Ren; Amanda Campbell; Huiqing Fang; Shalini Gautam; Saranya Elavazhagan; Kavin Fatehchand; Payal Mehta; Andrew Stiff; Brenda F Reader; Xiaokui Mo; John C Byrd; William E Carson; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

6.  Covalent Tethering of Fragments For Covalent Probe Discovery.

Authors:  Stefan G Kathman; Alexander V Statsyuk
Journal:  Medchemcomm       Date:  2016-01-28       Impact factor: 3.597

7.  Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.

Authors:  Leila Kokabee; Xianhui Wang; Christopher J Sevinsky; Wei Lin Winnie Wang; Lindsay Cheu; Sridar V Chittur; Morteza Karimipoor; Martin Tenniswood; Douglas S Conklin
Journal:  Cancer Biol Ther       Date:  2015-09-18       Impact factor: 4.742

8.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

9.  Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.

Authors:  Chih-Hang Anthony Tang; Sujeewa Ranatunga; Crystina L Kriss; Christopher L Cubitt; Jianguo Tao; Javier A Pinilla-Ibarz; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

10.  Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.

Authors:  Wooyoung Hur; Anastasia Velentza; Sungjoon Kim; Laura Flatauer; Xinnong Jiang; David Valente; Daniel E Mason; Melissa Suzuki; Brad Larson; Jianming Zhang; Anna Zagorska; Michael Didonato; Advait Nagle; Markus Warmuth; Steven P Balk; Eric C Peters; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2008-07-18       Impact factor: 2.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.